<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="sub-topic" /><meta name="keywords" content="Cytokine modulators: rheumatoid arthritis; Adalimumab: rheumatic diseases; Certolizumab pegol; Etanercept: rheumatic diseases; Ankylosing spondylitis; Golimumab; Infliximab: rheumatic diseases; Rituximab: rheumatic diseases; Abatacept; Anakinra; Belimumab; Tocilizumab" /><meta name="IX" content="Cytokine modulators: rheumatoid arthritis; Adalimumab: rheumatic diseases; Certolizumab pegol; Etanercept: rheumatic diseases; Ankylosing spondylitis; Golimumab; Infliximab: rheumatic diseases; Rituximab: rheumatic diseases; Abatacept; Anakinra; Belimumab; Tocilizumab" /><title>Cytokine modulators: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../383/theme.css" /><link type="text/css" rel="stylesheet" href="204/style.css" /><link type="image/x-icon" rel="shortcut icon" href="../../favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="PHP0-publication-information.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="PHP6607-cytokine-modulators.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.8/jquery.min.js"></script><script type="text/javascript" src="../../383/scripts.js"></script><style type="text/css">
          .contentsbox { position: fixed; z-index:1001; }
          .contentsbox_wrap { overflow: hidden; width: 20px; height: 130px; position: absolute; left: 0; top: 0; }
        </style><!--[if IE 8]>
          <style type="text/css">
          #p1 {
          float: left;
          padding-bottom: 15em;
          }
          </style>
          <![endif]--><!--[if lte IE 8]>
          <style type="text/css">
          #start-search input {
          height: 28px;
          padding-top: 8px;
          }
          @media screen {
          #pV {
          display: block !important;
          }
          }
          </style>
          <![endif]--><!--[if IE 7]>
          <style type="text/css">
          #start-search input {
          position: absolute !important;
          left: 0;
          top: 0;
          }
          .as-shadow {
          margin-left: -4px !important;
          color: silver;
          }
          </style>
          <![endif]--><!--[if lte IE 7]>
          <style type="text/css">
          .menu {
          height: 1%;
          }
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }

          #account-info ul li a {
          width: 12em;
          }
          #opts ul li span {
          width: 12em;
          }
          div.as-select ul li ul li span {
          width: 40em;
          }
          div.menu ul li ul li {
          float: left !important;
          }
          #pQ fieldset, #qd, #input-box, #pub-list, #start-search, #end-search {
          display: inline;
          float: left;
          height: 100%;
          padding: 0;
          margin: 0;
          position: relative;
          }
          #hM a, #hM a img {
          border: none;
          display: inline-block;
          float: left;
          }
          #qd input {
          float: left;
          display: inline-block !important;
          }
          #start-search input {
          height: 28px;
          padding-top: 8px !important;
          }
          #end-search, #end-search input {
          height: 36px !important;
          }
          #hM, #content, #searchForm, #purple-menu {
          width: expression(document.body.clientWidth > 63 * parseInt(document.body.currentStyle.fontSize) ? '63em': 'auto');
          margin: 0 auto;
          }
          #pQ {
          z-index: 1;
          }
          </style>
          <![endif]--><!--[if lte IE 6]>
          <style type="text/css">
          body {
          height: 100%;
          }
          div.menu ul li a, div.menu ul li span {
          display: inline-block;
          }
          div.menu ul li ul li {
          clear: both;
          }
          div.as-select ul li span {
          height: 20px;
          padding-top: 16px;
          padding-left: 1em;
          padding-bottom: 0;
          padding-left: 1em;
          margin: 4px 0;
          border-right: 1px solid #888;
          background-image: url("images/dropdown_img.png");
          background-repeat: repeat-x;
          overflow-x: hidden;
          }
          div.as-select ul li ul li span {
          font: bold 10px Verdana !important;
          padding: 4px 1em !important;
          color: #2D2D2D;
          background: white;
          text-decoration: none !important;
          white-space: nowrap;
          border: none !important;
          float: left;
          }
          div.menu span.hover {
          background: #8F1F8D;
          color: white;
          }
          </style>
          <![endif]--></head><body><!--[if lte IE 6]>
          <script type="text/javascript">
          jQuery(document).ready(function($) {
          $('a.mclogo').html('<img src="images/mc_logo.gif" class="logo" />');
          });
          </script>
          <![endif]--><?highlighter off?><div id="hC"><div id="vH"><div id="pU"><a class="mclogo" href="http://www.medicinescomplete.com/about/"><img class="logo" src="../../images/mc_logo.png" alt="MedicinesComplete" /></a><div id="hM"><div id="vM" class="menu"><ul><li><a href="http://www.medicinescomplete.com/mc/index.htm">Home</a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm">Help</a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=PHP6607-cytokine-modulators.htm">Feedback</a></li><li id="account-info"><a href="http://www.medicinescomplete.com/mc/account.htm">BNF.org Free Access</a><ul><li><a href="http://www.medicinescomplete.com/mc/account.htm">My Account</a></li><li><a href="http://www.medicinescomplete.com/mc/subscribe.htm">Subscribe</a></li><li><a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li><a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul></li></ul></div><a id="pD" accesskey="s" rel="bookmark" href="PHP6607-cytokine-modulators.htm#pB" title="Skip Navigation">Skip Navigation</a></div></div><div id="pA"><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 13 Mar 2013 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="search-in">Publication</label><label for="q">Search for</label><div id="qd"><div id="start-search"><div class="as-select menu" id="pub-list"><ul><li><span>British National Formulary</span><ul></ul></li></ul></div><div id="input-box"><input type="text" id="q" name="q" accesskey="4" /></div></div><div id="end-search"><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div></div></div><div id="pH"><div id="pN"><div id="pT"><!--[if lte IE 7]>
             
            <![endif]--><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF March 2013</a> &gt; <a href="PHP6372-musculoskeletal-and-joint-diseases.htm">10 Musculoskeletal and joint diseases</a> &gt; <a href="PHP6373-drugs-used-in-rheumatic-diseases-and-gout.htm">10.1 Drugs used in rheumatic diseases and gout</a> &gt; <a href="PHP6554-drugs-that-suppress-the-rheumatic-disease-process.htm">10.1.3 Drugs that suppress the rheumatic disease process</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="PHP6599-methotrexate.htm" title="Previous: METHOTREXATE">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="PHP6626-abatacept.htm" title="Next: ABATACEPT">Next page</a> ►</div></div></div></div><div id="content"><div id="p1"><div id="pB"><?highlighter on?><h1>Cytokine modulators</h1><?highlighter off?><?highlighter on?><div id="pC" class="jN"><p>Cytokine modulators should be used under specialist supervision.</p><p>Adalimumab, certolizumab pegol, etanercept, golimumab, and infliximab inhibit the activity of tumour necrosis factor alpha (TNF-α).</p><p id="PHP6608"><strong>Adalimumab</strong> is licensed for moderate to severe active <em>rheumatoid arthritis</em> when response to other disease-modifying antirheumatic drugs (including methotrexate) has been inadequate (see also NICE guidance <a title="BNF:target-block: NICE guidance cytokine modulators and the treatment of rheumatoid arthritis" href="PHP6607-cytokine-modulators.htm#PHP6614">October 2007</a> and <a title="BNF:target-block: NICE guidance cytokine modulators for treatment of rheumatoid arthritis after TNF failure" href="PHP6607-cytokine-modulators.htm#PHP6615">August 2010</a>); it is also licensed for severe, active, and progressive disease in adults not previously treated with methotrexate. In the treatment of rheumatoid arthritis, adalimumab should be used in combination with methotrexate, but it can be given alone if methotrexate is inappropriate. Adalimumab is also licensed for the treatment of active and progressive <em>psoriatic arthritis</em> (see also <a title="target-block: NICE guidance Etanercept and infliximab for the treatment of psoriatic arthritis" href="PHP6607-cytokine-modulators.htm#PHP6618">NICE guidance</a>) and severe active <em>ankylosing spondylitis</em> (see also <a title="BNF:target-block: NICE guidance Cytokine modulators for the treatment of ankylosing spondylitis" href="PHP6607-cytokine-modulators.htm#PHP6616">NICE guidance</a>) that have not responded adequately to other disease-modifying antirheumatic drugs. It is also licensed for the treatment of severe axial spondyloarthritis without radiographic evidence of ankylosing spondylitis but with objective signs of inflammation, in patients who have had an inadequate response to, or are intolerant of NSAIDs. For the role of adalimumab in inflammatory bowel disease, see <a title="monograph-family: Cytokine modulators" href="PHP535-cytokine-modulators.htm">section 1.5.3</a>. For the role of adalimumab in plaque psoriasis, see <a title="sub-section: Drugs affecting the immune response" href="PHP7766-drugs-affecting-the-immune-response.htm">section 13.5.3</a>. For the role of adalimumab in juvenile idiopathic arthritis see <a title="Cytokine modulators" href="http://www.medicinescomplete.com/mc/bnfc/current/PHP14387.htm"><em>BNF for Children</em></a>.</p><p id="PHP6609"><strong>Certolizumab pegol</strong> is licensed for use in patients with moderate to severe active <em>rheumatoid arthritis</em> when response to disease-modifying antirheumatic drugs (including methotrexate) has been inadequate (see also NICE guidance, below). Certolizumab pegol can be used in combination with methotrexate, or as a monotherapy if methotrexate is not tolerated or is contra-indicated.</p><div id="PHP19166" class="cI"><p class="cAE">NICE guidance</p><h3 class="cT">Certolizumab pegol for the treatment of rheumatoid arthritis (February 2010)</h3><p>Certolizumab pegol is an option for the treatment of patients with rheumatoid arthritis only if:</p><ul><li><p>certolizumab pegol is used as described in the NICE guidance (October 2007) for other tumour necrosis factor (TNF) inhibitors, (see <a title="BNF:target-block: NICE guidance cytokine modulators and the treatment of rheumatoid arthritis" href="PHP6607-cytokine-modulators.htm#PHP6614">Adalimumab, Etanercept and Infliximab for the treatment of Rheumatoid Arthritis</a>, below) <em>and</em></p> </li><li><p>the manufacturer provides the first 12 weeks of certolizumab pegol (10 prefilled 200-mg syringes) free of charge to all patients starting treatment.</p> </li></ul><p><a href="http://www.nice.org.uk/TA186">www.nice.org.uk/TA186</a></p></div><p id="PHP6610"><strong>Etanercept</strong> is licensed for the treatment of moderate to severe active <em>rheumatoid arthritis</em> either alone or in combination with methotrexate when the response to other disease-modifying antirheumatic drugs is inadequate and in severe, active and progressive <em>rheumatoid arthritis</em> in patients not previously treated with methotrexate (see also NICE guidance <a title="BNF:target-block: NICE guidance cytokine modulators and the treatment of rheumatoid arthritis" href="PHP6607-cytokine-modulators.htm#PHP6614">October 2007</a> and <a title="BNF:target-block: NICE guidance cytokine modulators for treatment of rheumatoid arthritis after TNF failure" href="PHP6607-cytokine-modulators.htm#PHP6615">August 2010</a>). It is also licensed for the treatment of active and progressive <em>psoriatic arthritis</em> inadequately responsive to other disease-modifying antirheumatic drugs (see also <a title="BNF:target-block: NICE guidance Etanercept and infliximab for the treatment of psoriatic arthritis" href="PHP6607-cytokine-modulators.htm#PHP6618">NICE guidance</a>), and for severe <em>ankylosing spondylitis</em> inadequately responsive to conventional therapy (see also <a title="BNF:target-block: NICE guidance Cytokine modulators for the treatment of ankylosing spondylitis" href="PHP6607-cytokine-modulators.htm#PHP6616">NICE guidance</a>). For the role of etanercept in juvenile idiopathic arthritis see <a title="Cytokine modulators" href="http://www.medicinescomplete.com/mc/bnfc/current/PHP14387.htm"><em>BNF for Children</em></a>. For the role of etanercept in plaque psoriasis, see <a title="sub-section: Drugs affecting the immune response" href="PHP7766-drugs-affecting-the-immune-response.htm">section 13.5.3</a>.</p><p id="PHP6611"><strong>Golimumab</strong> is licensed in combination with methotrexate for the treatment of moderate to severe active <em>rheumatoid arthritis</em> when response to disease-modifying antirheumatic drug (DMARD) therapy (including methotrexate) has been inadequate (see also NICE guidance below); it is also licensed in combination with methotrexate for patients with severe, active, and progressive rheumatoid arthritis not previously treated with methotrexate. Golimumab is also licensed for the treatment of active and progressive <em>psoriatic arthritis</em>, as monotherapy or in combination with methotrexate, when response to DMARD therapy has been inadequate (see also NICE guidance below); it is also licensed for the treatment of severe active <em>ankylosing spondylitis</em> when there is an inadequate response to conventional treatment (see also NICE guidance below).</p><p>The <a title="NICE and Scottish Medicines Consortium" href="PHP60-general-guidance.htm#PHP18530"><em>Scotttish Medicines Consortium</em></a> has advised (June 2012) that golimumab (<em>Simponi</em>®) is accepted for restricted use within NHS Scotland at a dose of 50 mg, alone or in combination with methotrexate, for the treatment of active and progressive psoriatic arthritis in adults whose disease has not responded to adequate trials of at least two standard DMARDs, administered either individually or in combination.</p><div id="PHP19167" class="cI"><p class="cAE">NICE guidance</p><h3 class="cT">Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying antirheumatic drugs (June 2011)</h3><p>Golimumab, in combination with methotrexate, is an option for the treatment of rheumatoid arthritis in adults who have had an inadequate response to conventional disease-modifying antirheumatic drugs (DMARDs) only, including methotrexate, if:</p><ul><li><p>golimumab is used as described in the NICE guidance (October 2007) for other tumour necrosis factor (TNF) inhibitors (see <a title="BNF:target-block: NICE guidance cytokine modulators and the treatment of rheumatoid arthritis" href="PHP6607-cytokine-modulators.htm#PHP6614">Adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis</a>), <em>and</em></p> </li><li><p>the manufacturer provides the 100-mg dose of golimumab at the same price as the 50-mg dose</p> </li></ul><p>Alternatively, golimumab, in combination with methotrexate, is an option for the treatment of rheumatoid arthritis in adults who have had an inadequate response to DMARDs including a TNF inhibitor, if:</p><ul><li><p>golimumab is used as described in the NICE guidance (August 2010) for other TNF inhibitors (see <a title="BNF:target-block: NICE guidance cytokine modulators for treatment of rheumatoid arthritis after TNF failure" href="PHP6607-cytokine-modulators.htm#PHP6615">Adalimumab, etanercept, infliximab, rituximab, and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor</a>), <em>and</em></p> </li><li><p>the manufacturer provides the 100-mg dose of golimumab at the same price as the 50-mg dose</p> </li></ul><p><a href="http://www.nice.org.uk/TA225">www.nice.org.uk/TA225</a></p></div><div id="PHP19168" class="cI"><p class="cAE">NICE guidance</p><h3 class="cT">Golimumab for the treatment of psoriatic arthritis (April 2011)</h3><p>Golimumab is an option for the treatment of active and progressive psoriatic arthritis in adults only if:</p><ul><li><p>golimumab is used as described in the NICE guidance (August 2010) for other tumour necrosis factor (TNF) inhibitors (see <a title="BNF:target-block: NICE guidance Etanercept and infliximab for the treatment of psoriatic arthritis" href="PHP6607-cytokine-modulators.htm#PHP6618">Etanercept, infliximab, and adalimumab for the treatment of psoriatic arthritis</a>), <em>and</em></p> </li><li><p>the manufacturer provides the 100-mg dose of golimumab at the same price as the 50-mg dose</p> </li></ul><p><a href="http://www.nice.org.uk/TA220">www.nice.org.uk/TA220</a></p></div><div id="PHP19169" class="cI"><p class="cAE">NICE guidance</p><h3 class="cT">Golimumab for the treatment of ankylosing spondylitis (August 2011)</h3><p>Golimumab is an option for the treatment of severe, active ankylosing spondylitis in adults only if:</p><ul><li><p>Golimumab is used as described in the NICE guidance (May 2008) for adalimumab and etanercept (see <a title="BNF:target-block: NICE guidance Cytokine modulators for the treatment of ankylosing spondylitis" href="PHP6607-cytokine-modulators.htm#PHP6616">Adalimumab, etanercept, and infliximab for the treatment of ankylosing spondylitis</a>), <em>and</em></p> </li><li><p>the manufacturer provides the 100-mg dose of golimumab at the same price as the 50-mg dose</p> </li></ul><p>Patients who are already receiving golimumab for the treatment of severe, active ankylosing spondylitis who do not fulfil the criteria for treatment with adalimumab and etanercept, described in the NICE guidance (May 2008), can continue treatment until they and their specialist consider it appropriate to stop. </p><p><a href="http://www.nice.org.uk/TA233">www.nice.org.uk/TA233</a></p></div><p id="PHP6612"><strong>Infliximab</strong> is licensed for the treatment of active <em>rheumatoid arthritis</em> in combination with methotrexate when the response to other disease-modifying antirheumatic drugs, including methotrexate, is inadequate (see also NICE guidance <a title="BNF:target-block: NICE guidance cytokine modulators and the treatment of rheumatoid arthritis" href="PHP6607-cytokine-modulators.htm#PHP6614">October 2007</a> and <a title="BNF:target-block: NICE guidance cytokine modulators for treatment of rheumatoid arthritis after TNF failure" href="PHP6607-cytokine-modulators.htm#PHP6615">August 2010</a>); it is also licensed in combination with methotrexate for patients not previously treated with methotrexate or other DMARDs who have severe, active, and progressive rheumatoid arthritis. Infliximab is also licensed for the treatment of <em>ankylosing spondylitis</em>, in patients with severe axial symptoms who have not responded adequately to conventional therapy (but see also <a title="BNF:target-block: NICE guidance Cytokine modulators for the treatment of ankylosing spondylitis" href="PHP6607-cytokine-modulators.htm#PHP6616">NICE guidance</a>) and in combination with methotrexate (or alone if methotrexate is not tolerated or is contra-indicated) for the treatment of active and progressive <em>psoriatic arthritis</em> which has not responded adequately to disease-modifying antirheumatic drugs (see also <a title="BNF:target-block: NICE guidance Etanercept and infliximab for the treatment of psoriatic arthritis" href="PHP6607-cytokine-modulators.htm#PHP6618">NICE guidance</a>).</p><p id="PHP6613"><strong>Rituximab</strong> is licensed in combination with methotrexate for the treatment of severe active <em>rheumatoid arthritis</em> in patients whose condition has not responded adequately to other disease-modifying antirheumatic drugs (including one or more tumour necrosis factor inhibitors) or who are intolerant of them (see also <a title="BNF:target-block: NICE guidance cytokine modulators for treatment of rheumatoid arthritis after TNF failure" href="PHP6607-cytokine-modulators.htm#PHP6615">NICE guidance</a>). For the role of rituximab in malignant disease, see <a title="BNF:sub-section: Anti-lymphocyte monoclonal antibodies" href="PHP5649-anti-lymphocyte-monoclonal-antibodies.htm">section 8.2.3</a>.</p><div id="PHP6614" class="cI"><p class="cAE">NICE guidance</p><h3 class="cT">Adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis (October 2007)</h3><p>The tumour necrosis factor alpha (TNF-α) inhibitors adalimumab, etanercept, and infliximab are options for the treatment of adults with active rheumatoid arthritis who have failed to respond to at least 2 disease-modifying antirheumatic drugs (DMARDs), including methotrexate (unless contra-indicated). TNF-α inhibitors should be given in combination with methotrexate; however, when methotrexate cannot be used because of intolerance or contra-indications, adalimumab or etanercept can be given as monotherapy.<br /></p><p>Adalimumab, etanercept, and infliximab should be withdrawn if response is not adequate within 6 months. Response to treatment should be monitored at least every 6 months in patients who respond initially; treatment should be withdrawn if response is not maintained. An alternative TNF-α inhibitor may be considered for patients in whom treatment is withdrawn because of intolerance before the initial 6-month assessment of efficacy.<br /></p><p>Use of TNF-α inhibitors for the treatment of severe, active, and progressive rheumatoid arthritis in adults not previously treated with methotrexate or other DMARDs is not recommended.</p><p><a href="http://www.nice.org.uk/TA130">www.nice.org.uk/TA130</a></p></div><div id="PHP6615" class="cI"><p class="cAE">NICE guidance</p><h3 class="cT">Adalimumab, etanercept, infliximab, rituximab, and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor (August 2010)</h3><p>Rituximab, in combination with methotrexate, is an option for the treatment of severe active rheumatoid arthritis in adults who have had an inadequate response to, or are intolerant of, other disease-modifying antirheumatic drugs (DMARDs), including at least 1 tumour necrosis factor (TNF) inhibitor. Repeat courses of rituximab should be given no more frequently than every 6 months, and should only be continued if an adequate response is achieved and maintained.<br /></p><p>Adalimumab, etanercept, infliximab, or abatacept, in combination with methotrexate, are options for the treatment of severe active rheumatoid arthritis in adults who have had an inadequate response to, or have an intolerance of, other DMARDs including at least 1 TNF inhibitor, and who cannot use rituximab because of contra-indications or intolerance. In patients who cannot use methotrexate because of intolerance or contra-indications, adalimumab or etanercept can be given as monotherapy. Treatment should be continued only if there is adequate response. Patients should be monitored at least every 6 months.</p><p><a href="http://www.nice.org.uk/TA195">www.nice.org.uk/TA195</a></p></div><div id="PHP6616" class="cI"><p class="cAE">NICE guidance</p><h3 class="cT">Adalimumab, etanercept, and infliximab for the treatment of ankylosing spondylitis (May 2008)</h3><p>Adalimumab or etanercept are treatment options for adults with severe active ankylosing spondylitis whose disease satisfies specific criteria for diagnosis where there is confirmation of sustained active spinal disease, and where treatment with two or more NSAIDs taken sequentially at maximum tolerated or recommended doses for 4 weeks has failed to control symptoms.</p><p>Response to adalimumab or etanercept treatment should be assessed at 12-week intervals and continued only if response is adequate. If response to treatment is not maintained, a repeat assessment should be made after a further 6 weeks and treatment discontinued if there is an inadequate response. Patients who are intolerant of adalimumab or etanercept during the initial 12 weeks may receive the alternative TNF-α inhibitor (adalimumab or etanercept). However an alternative TNF-α inhibitor is not recommended in patients who fail to respond initially or fail to maintain an adequate response.</p><p>Infliximab is not recommended for the treatment of ankylosing spondylitis. Patients who are already receiving infliximab for the treatment of ankylosing spondylitis can continue treatment until they and their specialist consider it appropriate to stop.</p><p>See full NICE guidance for specific criteria to diagnose severe active ankylosing spondylitis, confirm sustained active spinal disease, and assess response to treatment.</p><p><a href="http://www.nice.org.uk/TA143">www.nice.org.uk/TA143</a></p></div><div id="PHP6618" class="cI"><p class="cAE">NICE guidance</p><h3 class="cT">Etanercept, infliximab, and adalimumab for the treatment of psoriatic arthritis (August 2010)</h3><p>Etanercept, infliximab, or adalimumab are recommended for the treatment of active and progressive psoriatic arthritis in adults who have peripheral arthritis with at least 3 tender joints and at least 3 swollen joints, and who have not responded adequately to at least 2 standard disease-modifying antirheumatic drugs (used alone or in combination).<br /></p><p>Etanercept, infliximab, and adalimumab should be discontinued if there is an inadequate response at 12 weeks.</p><p><a href="http://www.nice.org.uk/TA199">www.nice.org.uk/TA199</a></p></div><div id="PHP6619"><h2>Side-effects</h2><p>Adalimumab, certolizumab pegol, etanercept, golimumab, infliximab, and rituximab have been associated with infections, sometimes severe, including tuberculosis, septicaemia, and hepatitis B reactivation. Other side-effects include nausea, abdominal pain, worsening heart failure, hypersensitivity reactions, fever, headache, depression, antibody formation (including lupus erythematosus-like syndrome), pruritus, injection-site reactions, and blood disorders (including anaemia, leucopenia, thrombocytopenia, pancytopenia, and aplastic anaemia).</p></div><p id="PHP6620"><strong>Abatacept</strong> prevents the full activation of T-lymphocytes. It is licensed for moderate to severe active <em>rheumatoid arthritis</em> in combination with methotrexate, in patients unresponsive to other disease-modifying antirheumatic drugs (including methotrexate or a tumour necrosis factor (TNF) inhibitor); see also NICE guidance (<a title="BNF:target-block: NICE guidance cytokine modulators for treatment of rheumatoid arthritis after TNF failure" href="PHP6607-cytokine-modulators.htm#PHP6615">August 2010</a>) and (<a title="BNF:target-block: Abatacept NICE guidance rheumatoid arthritis" href="PHP6607-cytokine-modulators.htm#PHP6621">August 2011</a>). For the role of abatacept in juvenile idiopathic arthritis see <a title="Cytokine modulators" href="http://www.medicinescomplete.com/mc/bnfc/current/PHP14387.htm"><em>BNF for Children</em></a>. Abatacept is not recommended for use in combination with TNF inhibitors.</p><p>The <a title="BNF:target-block: NICE and Scottish Medicines Consortium" href="PHP60-general-guidance.htm#PHP70"><em>Scottish Medicines Consortium</em></a>  has advised (October 2011) that abatacept (<em>Orencia</em>®) is accepted for restricted use within NHS Scotland for adults with severe active rheumatoid arthritis, in line with NICE guidance <a title="BNF:target-block: NICE guidance cytokine modulators for treatment of rheumatoid arthritis after TNF failure" href="PHP6607-cytokine-modulators.htm#PHP6615"><em>Adalimumab, etanercept, infliximab, rituximab, and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor</em></a> (August 2010).</p><div id="PHP6621" class="cI"><p class="cAE">NICE guidance</p><h3 class="cT">Abatacept for the treatment of rheumatoid arthritis after the failure of conventional disease-modifying antirheumatic drugs (August 2011)</h3><p>Abatacept, in combination with methotrexate, is <strong>not</strong> recommended for the treatment of moderate to severe active rheumatoid arthritis in adults who have had an inadequate response to one or more conventional disease-modifying antirheumatic drugs, including methotrexate. Patients who are already receiving abatacept for this indication should continue treatment until they and their specialist consider it appropriate to stop.</p><p><a href="http://www.nice.org.uk/TA234">www.nice.org.uk/TA234</a></p></div><p id="PHP6622"><strong>Anakinra</strong> inhibits the activity of interleukin-1. Anakinra (in combination with methotrexate) is licensed for the treatment of <em>rheumatoid arthritis</em> which has not responded to methotrexate alone; it is not, however, recommended for routine management of <em>rheumatoid arthritis</em>, see NICE guidance below. </p><p>The <a title="BNF:target-block: NICE and Scottish Medicines Consortium" href="PHP60-general-guidance.htm#PHP70"><em>Scottish Medicines Consortium</em></a> has advised (July 2002) that anakinra is <strong>not</strong> recommended for the treatment of rheumatoid arthritis within NHS Scotland.</p><div id="PHP19170" class="cI"><p class="cAE">NICE guidance</p><h3 class="cT">Anakinra for the treatment of rheumatoid arthritis (February 2009)</h3><p>Anakinra is <strong>not</strong> recommended for the treatment of rheumatoid arthritis except when used in a controlled long-term clinical study. Patients who are already receiving anakinra for rheumatoid arthritis should continue treatment until they and their specialist consider it appropriate to stop.</p></div><p id="PHP6623"><strong>Belimumab</strong> inhibits the activity of B-lymphocyte stimulator. Belimumab is licensed as adjunctive therapy in patients with active, autoantibody-positive systemic lupus erythematosus with a high degree of disease activity despite standard therapy. Infusion-related side-effects are reported commonly with belimumab, including severe or life-threatening hypersensitivity and infusion reactions. These occur predominantly during the first 2 infusions. Delay in the onset of acute hypersensitivity reactions has been observed; patients should remain under clinical supervision for several hours following at least the first 2 infusions. Premedication with an antihistamine, with or without an antipyretic, may be considered.</p><p id="PHP6624"><strong>Tocilizumab</strong> antagonises the actions of interleukin-6. Tocilizumab is licensed for use in patients with moderate to severe active <em>rheumatoid arthritis</em> when response to at least one disease-modifying antirheumatic drug or tumour necrosis factor inhibitor has been inadequate, or in those who are intolerant of these drugs. Tocilizumab can be used in combination with methotrexate, or as monotherapy if methotrexate is not tolerated or is contra-indicated (see also NICE guidance below). For the role of tocilizumab in juvenile idiopathic arthritis see <a title="Cytokine modulators" href="http://www.medicinescomplete.com/mc/bnfc/current/PHP14387.htm"><em>BNF for Children</em></a>.</p><p>The <a title="NICE and Scottish Medicines Consortium" href="PHP60-general-guidance.htm#PHP70"><em>Scottish Medicines Consortium</em></a> has advised (August 2012) that tocilizumab (<em>RoActemra</em>®) is accepted for restricted use within NHS Scotland as monotherapy in patients who are intolerant to methotrexate or where continued treatment with methotrexate is inappropriate, for the treatment of moderate to severe active rheumatoid arthritis in adults who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs or tumour necrosis factor inhibitors, in accordance with the British Society for Rhematology guidance on prescribing TNF-α blockers in adults with rheumatoid arthritis (2005).</p><div id="PHP6625" class="cI"><p class="cAE">NICE guidance</p><h3 class="cT">Tocilizumab for the treatment of rheumatoid arthritis (February 2012)</h3><p id="PHP18498">Tocilizumab, in combination with methotrexate, is recommended as an option for the treatment of rheumatoid arthritis in adults if: </p><ul><li><p>the disease has responded inadequately to disease-modifying anti-rheumatic drugs (DMARDs) <strong>and</strong> is used as described for tumour necrosis factor (TNF) inhibitor treatments (specifically the recommendations on disease activity and treatment) in the NICE guidance (October 2007) <a title="NICE guidance cytokine modulators and the treatment of rheumatoid arthritis" href="PHP6607-cytokine-modulators.htm#PHP6614">Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis</a> <em>or</em></p></li><li><p>the disease has responded inadequately to DMARDs and a TNF inhibitor and the patient cannot receive rituximab beacause of contra-indications or intolerance, <strong>and</strong> tocilizumab is used as described for TNF inhibitor treatments (specifically the recommendations on disease activity) in the NICE guidance (August 2010) <a title="NICE guidance cytokine modulators for treatment of rheumatoid arthritis after TNF failure" href="PHP6607-cytokine-modulators.htm#PHP6615">Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor</a><em> or</em></p></li><li><p>the disease has responded inadequately to one or more TNF inhibitor treatments and to rituximab</p></li><li><p><strong>and</strong> the manufacturer provides tocilizumab with the discount agreed as part of the patient access scheme.</p></li></ul><p>Patients currently receiving tocilizumab for the treatment of rheumatoid arthritis who do not meet these criteria should have the option to continue treatment until they and their clinicians consider it appropriate to stop.</p><p><a href="http://www.nice.org.uk/TA247">www.nice.org.uk/TA247</a></p></div></div><div id="pS"><p>Sub-sections</p><ul class="jT"><li id="_PHP6626-abatacept"><a href="PHP6626-abatacept.htm" title="ABATACEPT">ABATACEPT</a></li><li id="_PHP6628-adalimumab"><a href="PHP6628-adalimumab.htm" title="ADALIMUMAB">ADALIMUMAB</a></li><li id="_PHP6633-anakinra"><a href="PHP6633-anakinra.htm" title="ANAKINRA">ANAKINRA</a></li><li id="_PHP6635-belimumab"><a href="PHP6635-belimumab.htm" title="BELIMUMAB">BELIMUMAB</a></li><li id="_PHP6637-certolizumab-pegol"><a href="PHP6637-certolizumab-pegol.htm" title="CERTOLIZUMAB PEGOL">CERTOLIZUMAB PEGOL</a></li><li id="_PHP6639-etanercept"><a href="PHP6639-etanercept.htm" title="ETANERCEPT">ETANERCEPT</a></li><li id="_PHP6644-golimumab"><a href="PHP6644-golimumab.htm" title="GOLIMUMAB">GOLIMUMAB</a></li><li id="_PHP6646-infliximab"><a href="PHP6646-infliximab.htm" title="INFLIXIMAB">INFLIXIMAB</a></li><li id="_PHP6651-rituximab"><a href="PHP6651-rituximab.htm" title="RITUXIMAB">RITUXIMAB</a></li><li id="_PHP6653-tocilizumab"><a href="PHP6653-tocilizumab.htm" title="TOCILIZUMAB">TOCILIZUMAB</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="PHP6599-methotrexate.htm">Previous: METHOTREXATE</a> | <a class="top" href="PHP6607-cytokine-modulators.htm#">Top</a> | <a accesskey="]" href="PHP6626-abatacept.htm">Next: ABATACEPT</a> ►</div></div></div></div><div id="pF"><div id="p2"><div id="pL"><div class="p4"><h2>Keep in touch</h2><ul><li><a href="http://www.pharmpress.com/?utm_source=medicinescomplete&amp;utm_medium=footer&amp;utm_campaign=medicinescomplete-referral">Pharmaceutical Press</a></li><li><a href="http://www.rpharms.com/">Royal Pharmaceutical Society</a></li><li><a href="http://www.pharmpress.com/mc-alerts.asp?utm_source=medicinescomplete&amp;utm_medium=footer&amp;utm_campaign=medicinescomplete-referral">Sign up for our eNewsletter</a></li><li><a href="http://twitter.com/#!/PharmPress/" class="p5"><img src="../../images/twitter.png" alt="Twitter logo" />Follow us on Twitter
              </a></li><li><a href="http://www.facebook.com/pages/Pharmaceutical-Press/296104187066918" class="p5"><img src="../../images/facebook.png" alt="Facebook logo" />Find us on Facebook
              </a></li></ul></div><div class="p4"><h2>Help and Support</h2><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a></li><li><a href="http://www.medicinescomplete.com/about/contact.htm">Contact Us</a></li><li><a href="privacy.htm" title="Cookie and Privacy Policy">Cookie and Privacy Policy</a></li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a></li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div><div class="p4"><h2>Provided for</h2><div id="cL"><img src="../../images/mylogo.png" alt="BNF.org Free Access" id="pI" /></div></div><div id="pX"><p><a href="PHP0-publication-information.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2013.  All rights reserved.</a></p><p><a href="http://www.medicinescomplete.com/mc/copyright.htm">MedicinesComplete © The Pharmaceutical Press 2013</a></p></div></div></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>